What is Erbitux, and how does it work?
Erbitux (cetuximab), in combination with radiation therapy, is a monoclonal antibody indicated for the initial treatment of locally or regionally advanced head and neck cancer of a specific type (squamous cell carcinoma).
Used alone, Erbitux is also approved to treat patients with head and neck cancers that have returned in the same location or spread to other parts of the body and for head and neck cancers that have progressed following platinum-based chemotherapy. Erbitux is also used on metastatic colorectal cancers that contain epidermal growth factor receptors.
What are the side effects of Erbitux?
The most common side effects of Erbitux include:
- rash,
- itching,
- dry or cracked skin,
- nail changes,
- headache,
- diarrhea,
- nausea,
- vomiting,
- upset stomach,
- weight loss,
- weakness, and
- respiratory, skin, and mouth infections.
Erbitux also can cause low blood magnesium, potassium, and calcium. Patients taking Erbitux should limit their exposure to the sun. Rare but serious side effects of Erbitux include:
- life-threatening allergic reactions and
- heart attacks, especially if the patient was also obtaining chemotherapy or radiotherapy.
WARNING
SERIOUS INFUSION REACTIONS and CARDIOPULMONARY ARREST
Infusion Reactions: Serious infusion reactions occurred with the administration of Erbitux in approximately 3% of patients in clinical trials, with fatal outcome reported in less than 1 in 1000. Immediately interrupt and permanently discontinue Erbitux infusion for serious infusion reactions.
Cardiopulmonary Arrest: Cardiopulmonary arrest and/or sudden death occurred in 2% of patients with squamous cell carcinoma of the head and neck treated with Erbitux and radiation therapy in Study 1 and in 3% of patients with squamous cell carcinoma of the head and neck treated with European Union (EU)- approved cetuximab in combination with platinum-based therapy with 5-fluorouracil (5-FU) in Study 2. Closely monitor serum electrolytes, including serum magnesium, potassium, and calcium, during and after Erbitux administration.

IMAGES
Colon Cancer Illustration Browse through our medical image collection to see illustrations of human anatomy and physiology See ImagesWhat is the dosage for Erbitux?
Recommended Dosage For Squamous Cell Carcinoma Of The Head And Neck (SCCHN)
In Combination With Radiation Therapy Or Platinum-Based Therapy And Fluorouracil
- The recommended initial dose is 400 mg/m² administered one week prior to initiating a course of radiation therapy or on the first day of platinum-based therapy and fluorouracil as a 120-minute intravenous infusion.
- The recommended subsequent dosage (all other infusions) is 250 mg/m² weekly as a 60-minute infusion for the duration of radiation therapy (6–7 weeks) or until disease progression or unacceptable toxicity when administered in combination with platinum-based therapy and fluorouracil.
- Complete Erbitux administration 1 hour prior to radiation therapy or platinum-based therapy with fluorouracil.
Monotherapy
- The recommended initial dose is 400 mg/m² administered as a 120-minute intravenous infusion.
- The recommended subsequent dosage (all other infusions) is 250 mg/m² weekly as a 60-minute infusion until disease progression or unacceptable toxicity.
Recommended Dosage For Colorectal Cancer (CRC)
Determine EGFR-expression status using FDA-approved tests prior to initiating treatment. Also confirm the absence of a Ras mutation prior to initiation of treatment with Erbitux. Information on FDA-approved tests for the detection of K-Ras mutations in patients with metastatic CRC is available at: http://www.fda.gov/medicaldevices/productsandmedicalprocedures/invitrodiagnostics/ucm301431.htm.
- The recommended initial dose, either as monotherapy or in combination with irinotecan or Folfiri (irinotecan, fluorouracil, leucovorin), is 400 mg/m² administered as a 120-minute intravenous infusion.
- The recommended subsequent dosage, either as monotherapy or in combination with irinotecan or Folfiri, is 250 mg/m² weekly as a 60-minute infusion until disease progression or unacceptable toxicity.
- Complete Erbitux administration 1 hour prior to irinotecan or Folfiri.
Premedication
Premedicate with a histamine-1 (H1) receptor antagonist intravenously 30-60 minutes prior to the first dose or subsequent doses as deemed necessary.
Dosage Modifications For Adverse Reactions
Reduce, delay, or discontinue Erbitux to manage adverse reactions as described in Table 1.
Table 1: Recommended Dosage Modifications for Adverse Reactions
Adverse Reaction | Severitya | Dosage Modification |
Infusion reactions | Grade 1 or 2 | Reduce the infusion rate by 50%. |
Grade 3 or 4 | Immediately and permanently, discontinue Erbitux. | |
Dermatologic toxicities and infectious sequelae (e.g., acneiform rash, mucocutaneous disease) | 1st occurrence; Grade 3 or 4 | Delay infusion 1 to 2 weeks; if condition improves, continue at 250 mg/m². If no improvement, discontinue Erbitux. |
2nd occurrence; Grade 3 or 4 | Delay infusion 1 to 2 weeks; if condition improves, continue at 200 mg/m². If no improvement, discontinue Erbitux. | |
3 rd occurrence; Grade 3 or 4 | Delay infusion 1 to 2 weeks; if condition improves, continue at 150 mg/m². If no improvement, discontinue Erbitux. | |
4th occurrence; Grade 3 or 4 | Discontinue Erbitux. | |
Pulmonary toxicity | Acute onset or worsening pulmonary symptoms | Delay infusion 1 to 2 weeks; if condition improves, continue at the dose that was being administered at the time of occurrence. If no improvement in 2 weeks or interstitial lung disease (ILD) is confirmed, discontinue Erbitux. |
aNational Cancer Institute (NCI) Common Toxicity Criteria (CTC), version 2.0. |
Is Erbitux safe to use while pregnant or breastfeeding?
- Based on findings from animal studies and its mechanism of action, Erbitux can cause fetal harm when administered to a pregnant woman.
- There are no available data for Erbitux exposure in pregnant women.
- In an animal reproduction study, intravenous administration of cetuximab once weekly to pregnant cynomolgus monkeys during the period of organogenesis resulted in an increased incidence of embryolethality and abortion.
- Disruption or depletion of EGFR in animal models results in impairment of embryo-fetal development including effects on
- placental,
- lung,
- cardiac,
- skin, and
- neural development.
- Human IgG is known to cross the placental barrier; therefore, cetuximab may be transmitted from the mother to the developing fetus.

SLIDESHOW
Colorectal Cancer: Symptoms, Signs, Screening, Stages See SlideshowSummary
Erbitux (cetuximab), in combination with radiation therapy, is a monoclonal antibody indicated for the initial treatment of locally or regionally advanced head and neck cancer of a specific type (squamous cell carcinoma). Erbitux is also used on metastatic colorectal cancers that contain epidermal growth factor receptors. The most common side effects of Erbitux include rash, itching, dry or cracked skin, nail changes, headache, diarrhea, nausea, vomiting, upset stomach, weight loss, weakness, and respiratory, skin, and mouth infections.
Multimedia: Slideshows, Images & Quizzes
-
Understanding Cancer: Metastasis, Stages of Cancer, and More
Learn the basics about cancer including types, causes, how it spreads, symptoms and signs, stages and treatment options. Read...
-
Colorectal Cancer: Symptoms, Signs, Screening, Stages
Colorectal cancer (colon cancer) is the cause of many cancer deaths. Learn about the warning signs, symptoms, screening process,...
-
Head and Neck Cancers: Symptoms and Treatments
Head and neck cancers include cancers of the throat, lips, nose, mouth, larynx, and salivary glands. They are more likely to...
-
Cancer-Fighting Foods: Resveratrol, Green Tea, and More
Experts have praised certain foods for their ability to reduce cancer risks. Learn which foods and eating strategies may help...
-
Colon Cancer: How Your Diet Can Affect Colorectal Cancer
Diet, including nutrient, antioxidant, and vitamin intake, affects colon cancer risk. Certain dietary factors either decrease or...
-
Top 10 Cancers Quiz
Take this quiz to learn the causes of cancer. Get the facts about the causes, symptoms, and treatments for the world's most...
-
Colorectal (Colon) Cancer Quiz: Test Your Medical IQ
What is colorectal (colon) cancer and who gets it? Take this quiz to find out how this disease may be prevented.
-
Head and Neck Cancer Quiz
Learn the facts about head and neck cancers.
-
Cancer: Does This Cause Cancer?
Everything gives you cancer, right? Not really. WebMD's slide show tells you about the research into cancer and cell phones,...
-
Cancer: How to Lower and Cut Your Risk of Cancer
About a third of all cases of cancer can be prevented. Find out how to lower your chances of getting it.
-
Cancer: Cancer 'Remedies' That Don't Work
You may have read about an all-natural cure for cancer. While many therapies are helpful, some aren't worth your time or money....
Related Disease Conditions
-
Cancer
Cancer is a disease caused by an abnormal growth of cells, also called malignancy. It is a group of 100 different diseases, and is not contagious. Cancer can be treated through chemotherapy, a treatment of drugs that destroy cancer cells.
-
Colon Polyps
Colon polyps are fleshy growths inside the colon lining that may become cancerous. Symptoms include rectal bleeding. Learn about causes, signs, treatment, and how to prevent colon cancer.
-
Colon Cancer (Colorectal Cancer)
Colon Cancer (Colorectal Cancer) is a malignancy that arises from the inner lining of the colon. Most, if not all, of these cancers, develop from colonic polyps. Removal of these precancerous polyps can prevent colon cancer.
-
Colon Cancer: 8 Early Warning Signs & 4 Stages
Colon cancer usually does not cause signs or symptoms in the early stages. As the cancer grows, signs may include blood in the stool, bowel habit changes, abdominal pain, and fatigue. Learn about stages and treatment of colon cancer.
-
Cancer Risk Factors and Causes
Though it's difficult to say why some people develop cancer while others don't, research shows that certain risk factors increase a person's odds of developing cancer. These risk factors include growing older, family history of cancer, diet, alcohol and tobacco use, and exposure to sunlight, ionizing radiation, certain chemicals, and some viruses and bacteria.
-
Which Cancer Is the Most Painful?
Cancer spreading to the bone is the most painful type of cancer. Pain can be caused by a tumor pressing on the nerves around the bone. As the tumor size increases, it can release chemicals that irritate the area around the tumor.
-
Is Cancer Contagious?
Cancer is an abnormal growth of cells. A variety of parasites and viruses have been linked to various cancers. Cancer may metastasize, spreading from its original location to other organs. If you have cancer, you should seek medical care immediately if you experience high fever, shortness of breath, intense headaches, vomiting blood or passing blood rectally, chest pain or moderate to severe weakness, passing out (fainting), mental status changes, or seizures.
-
Colon Cancer Prevention
Colorectal cancer is both curable and preventable if it is detected early and completely removed before the cancerous cells metastasize to other parts of the body. Colonoscopy and flexible sigmoidoscopy (along with digital rectal examination and stool occult blood testing) are both effective at preventing colo-rectal cancers and detecting early colo-rectal cancers.
-
Which Is the Deadliest Cancer?
Lung cancer is considered to be the most deadly cancer. More people die from lung cancer each year than from breast, colorectal and prostate cancer combined.
-
Cancer Pain
Cancer pain is a common experience that may result from the disease, treatment, or diagnostic procedure. Check out the center below for more medical references on cancer, including multimedia (slideshows, images, and quizzes), related disease conditions, treatment and diagnosis, medications, and prevention or wellness.
-
What Is the Most Common Head and Neck Cancer?
Cancer in the head and neck region may affect your mouth (oral cavity), tongue, parts of the throat (pharynx), nose or nasal sinuses, salivary glands, gums, tonsils, voice-box (larynx) and middle ear. Globally, approximately 550,000 people are diagnosed with head and neck cancer (HNC) every year.
Treatment & Diagnosis
- Colon Cancer
- Cancer: The Importance of Joining a Cancer Support Group with Selma Schimmel
- Cancer Survival and Attitude with Hamilton Jordan
- Cancer: Confronting Cancer with Humor
- Cancer and Green Tea
- Cancer Research: Going the Distance
- Cancer Pain Management with Ann Reiner
- Colon Cancer Update with The Cleveland Clinic
- Cancer Patients Need Proper Diet and Exercise
- Cancer: Living Well Despite with Win Boerckel
- Cancer Treatment: Writing to Heal with Margie Davis
- Colorectal Cancer Issues: An Update with Doctors
- Cancer: Childhood Cancer Survivors
- Colon Cancer Update: James Church, MD
- Cancer: Journaling to Save Your Life
- Cancer: Emotional Aftershocks: When Cancer Comes Back 10/30/02
- Colon Cancer Update
- Cancer FAQs
- Head and Neck Cancer FAQs
- Colorectal (Colon) Cancer FAQs
- Cancer,Stroke & Heart Attack Risks- ReducedThrough Walking
- Colon Cancer Prevention And Fiber?
- Cancer Care in the Elderly
- Colon Cancer and Polyp Screening Guidelines
- Cancer Survivor?
- Colon Cancer Silences Howard Keel
- Colon Cancer, The Genetic Factor
- Does HIV Cause Colorectal Cancer?
- 10 Cancer Symptoms That Men Ignore
- Cancer Prevention: The Anticancer Diet
Medications & Supplements
Subscribe to MedicineNet's Cancer Report Newsletter
By clicking "Submit," I agree to the MedicineNet Terms and Conditions and Privacy Policy. I also agree to receive emails from MedicineNet and I understand that I may opt out of MedicineNet subscriptions at any time.
Health Solutions From Our Sponsors

Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.